These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7780090)

  • 1. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.
    Sauret J; Hernández-Flix S; Castro E; Hernández L; Ausina V; Coll P
    Tuber Lung Dis; 1995 Apr; 76(2):104-8. PubMed ID: 7780090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.
    Ahn CH; Lowell JR; Ahn SS; Ahn SI; Hurst GA
    Am Rev Respir Dis; 1983 Dec; 128(6):1048-50. PubMed ID: 6650978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease.
    Moon SM; Choe J; Jhun BW; Jeon K; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ
    Respir Med; 2019 Mar; 148():37-42. PubMed ID: 30827472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
    Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.
    Evans SA; Colville A; Evans AJ; Crisp AJ; Johnston ID
    Thorax; 1996 Dec; 51(12):1248-52. PubMed ID: 8994524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease.
    Santin M; Dorca J; Alcaide F; Gonzalez L; Casas S; Lopez M; Guerra MR
    Eur Respir J; 2009 Jan; 33(1):148-52. PubMed ID: 19118226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy.
    Campbell IA
    Tuber Lung Dis; 1995 Dec; 76(6):583. PubMed ID: 8593385
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.
    Lancet; 1975 Jan; 1(7899):119-24. PubMed ID: 46047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary Mycobacterium fortuitum infection with multiple nodular shadows in a healthy man].
    Inoue T; Tanaka E; Sakuramoto M; Maeda Y; Maniwa K; Taguchi Y
    Kekkaku; 2004 Oct; 79(10):573-7. PubMed ID: 15631109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
    Research Committee of the British Thoracic Society
    Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fever and thin-walled cavitary lung lesions].
    Ramos A; Daza R; Alvarez-Espejo T; Guzmán MF
    Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):363-4. PubMed ID: 19419797
    [No Abstract]   [Full Text] [Related]  

  • 13. Rifampin-resistant Mycobacterium kansasii.
    Wallace RJ; Dunbar D; Brown BA; Onyi G; Dunlap R; Ahn CH; Murphy DT
    Clin Infect Dis; 1994 May; 18(5):736-43. PubMed ID: 8075262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A; Nunn AJ; Enarson DA
    Lancet; 2004 Oct 2-8; 364(9441):1244-51. PubMed ID: 15464185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs.
    Ahn CH; Lowell JR; Ahn SS; Ahn S; Hurst GA
    Rev Infect Dis; 1981; 3(5):1028-34. PubMed ID: 7339800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response.
    Banks J; Hunter AM; Campbell IA; Jenkins PA; Smith AP
    Thorax; 1983 Apr; 38(4):271-4. PubMed ID: 6867979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. British Thoracic Association.
    Am Rev Respir Dis; 1982 Sep; 126(3):460-2. PubMed ID: 6751175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical and epidemiological study of disease caused by Mycobacterium kansasii in the metropolitan area of Bilbao, Spain].
    Leal Arranz MV; Gaafar A; Unzaga Barañano MJ; Crespo Notario JA; Cisterna Cáncer R; García Cebrián F
    Arch Bronconeumol; 2005 Apr; 41(4):189-96. PubMed ID: 15826528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.